NVO
Novo Nordisk A/S
NVO has lower modeled downside risk, despite its lower overall score.
SOPH
SOPHiA GENETICS S.A.
SOPH has the edge over NVO overall, supported by stronger fundamentals and stronger modeled upside.
NVO Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Stable | |
| Healthy |
NVO's revenue, profitability and balance sheet are currently healthy, and its cash flow is stable.
SOPH Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Under pressure | |
| Weak | |
| Unavailable |
SOPH's revenue is currently healthy, but its profitability and cash flow are under pressure. There isn't enough data to rate its balance sheet.
NVO PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 10x | $40.65 | — |
| Cheap | 14x | $53.56 | +32% |
| Fair | 27x | $103 | +154% |
| Expensive | 39x | $152 | +273% |
Historical ranges are pointers, not guarantees.
NVO's PE is 10x, but its earnings don't support one, so it isn't a reliable read right now.
SOPH PE Valuation
SOPH has no meaningful PE right now: it lost money over the past year.
NVO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Stable | |
| Growth | |
| Weakening | |
| Limited | |
| Low |
Analysts expect NVO's revenue to grow, but its profitability to weaken. However, they disagree widely on these estimates.
SOPH Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| High |
SOPH has the edge over NVO on the outlook, with more favorable earnings and profitability expectations.
NVO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | $3.89 | +4.9% |
| Q1 2026 | $4.07 | +17% |
| Q4 2025 | $3.42 | +1.8% |
| Q3 2025 | $3.47 | +10% |
| Q2 2025 | $3.71 | +24% |
| Q1 2025 | $3.49 | +18% |
| Q4 2024 | $3.36 | +21% |
| Q3 2024 | $3.15 | +27% |
NVO has the edge over SOPH on earnings quality, reporting a profit while its opponent remains loss making.
SOPH Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | -$1.15 | -$0.05 |
| Q1 2026 | -$1.18 | -$0.18 |
| Q4 2025 | -$1.17 | -$0.22 |
| Q3 2025 | -$1.12 | -$0.03 |
| Q2 2025 | -$1.10 | -$0.08 |
| Q1 2025 | -$1.00 | +$0.12 |
| Q4 2024 | -$0.95 | +$0.27 |
| Q3 2024 | -$1.09 | -$0.02 |
SOPH is still losing money, but less than at its worst: $1.15 per share over the past year, against $1.51 at its worst in late 2022.
NVO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $11.7B | +2.1% |
| Q1 2026 | $14.4B | +24% |
| Q4 2025 | $11.8B | -7.6% |
| Q3 2025 | $11.1B | +5.1% |
| Q2 2025 | $11.4B | +13% |
| Q1 2025 | $11.6B | +19% |
| Q4 2024 | $12.7B | +30% |
| Q3 2024 | $10.6B | +21% |
NVO's revenue is growing: $11.7B last quarter, up 2.1% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 34% | -9 points |
| Q1 2026 | 62% | +12 points |
| Q4 2025 | 40% | -2.8 points |
| Q3 2025 | 32% | -16 points |
| Q2 2025 | 44% | +5.4 points |
| Q1 2025 | 50% | +1 points |
| Q4 2024 | 43% | +2.2 points |
| Q3 2024 | 47% | +1.6 points |
NVO has the edge over SOPH on profitability, with a higher operating margin.
SOPH Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $23.3M | +27% |
| Q1 2026 | $21.7M | +22% |
| Q4 2025 | $21.7M | +22% |
| Q3 2025 | $19.5M | +23% |
| Q2 2025 | $18.3M | +16% |
| Q1 2025 | $17.8M | +13% |
| Q4 2024 | $17.7M | +4% |
| Q3 2024 | $15.9M | -2.8% |
SOPH has the edge over NVO on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -86% | +15 points |
| Q1 2026 | -80% | +11 points |
| Q4 2025 | -83% | +15 points |
| Q3 2025 | -92% | +5.1 points |
| Q2 2025 | -101% | -6.4 points |
| Q1 2025 | -90% | +29 points |
| Q4 2024 | -98% | +13 points |
| Q3 2024 | -97% | +4.6 points |
SOPH's operating margin was −86% last quarter, up 15 points from the same quarter a year ago.
NVO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $6.3B | +73% |
| Q1 2026 | $1.8B | +20% |
| Q4 2025 | -$5.4B | -$4.7B |
| Q3 2025 | $4.6B | -2.1% |
| Q2 2025 | $3.6B | -34% |
| Q1 2025 | $1.5B | +89% |
| Q4 2024 | -$632.6M | +$390.5M |
| Q3 2024 | $4.7B | +3.3% |
NVO has the edge over SOPH on cash generation, producing positive trailing cash flow while its opponent burns cash.
SOPH Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$10.4M | -$199K |
| Q1 2026 | -$17.1M | -$4.8M |
| Q4 2025 | -$9.3M | +$3.3M |
| Q3 2025 | -$8.9M | +$581K |
| Q2 2025 | -$10.2M | +$2.2M |
| Q1 2025 | -$12.2M | +$4.4M |
| Q4 2024 | -$12.5M | +$1M |
| Q3 2024 | -$9.5M | +$4.8M |
SOPH has burned cash in almost every quarter: −$46M over the past year, against −$44M the year before.
NVO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.3% | -12.9M shares |
| 1 year | -0.2% | -11M shares |
| 3 years | -1.5% | -66.8M shares |
| 5 years | -3.8% | -177M shares |
| Available history | -6.5% | -311M shares |
NVO has the edge over SOPH on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q2 2026 | $520M |
| Q1 2026 | $356.7M |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | $206.3M |
| Q4 2024 | $1.1B |
| Q3 2024 | $357.4M |
NVO spent $877M buying back its own shares over the past year, down 48% from the year before.
SOPH Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.8% | +2.7M shares |
| 1 year | +9.7% | +6.5M shares |
| 3 years | +14% | +9.3M shares |
| 5 years | +17% | +10.5M shares |
| Available history | +92% | +35.5M shares |
SOPH has 74M diluted shares, up 9.7% from a year ago.
| Quarter | Spent |
|---|---|
| Q2 2026 | — |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | — |
| Q3 2024 | — |
SOPH hasn't bought back shares in the past year.
NVO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 0.5x | Very low |
| Q1 2026 | 0.7x | Very low |
| Q4 2025 | 0.6x | Very low |
| Q3 2025 | 0.4x | Very low |
| Q2 2025 | 0.5x | Very low |
| Q1 2025 | 0.5x | Very low |
| Q4 2024 | 0.6x | Very low |
| Q3 2024 | -0.0x | Very low |
NVO's net debt is less than a year of its operating earnings (EBITDA).
SOPH Net Leverage
SOPH's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
NVO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.0 | Neutral |
| Stochastic | 27.0 | Neutral |
NVO's weekly RSI is 43 (neutral) and its Stochastic is 27 (neutral).
SOPH Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.8 | Neutral |
| Stochastic | 56.5 | Neutral |
SOPH's weekly RSI is 59 (neutral) and its Stochastic is 57 (neutral).
NVO PE vs Healthcare Sector
| Metric | NVO | Sector median | Relative |
|---|---|---|---|
| PE | 10x | 26x | 60% below |
| PE % | 6 | 29 | 23 pts below |
NVO is trading at 10x earnings, a 60% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
SOPH PE vs Healthcare Sector
SOPH has no meaningful PE right now: it lost money over the past year.
NVO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $39.2 | 3.7% above |
| 20 week MA | $43.9 | 7.4% below |
| 50 week MA | $45.3 | 10% below |
| 100 week MA | $56.3 | 28% below |
| 200 week MA | $80.7 | 50% below |
NVO has bounced recently, but its long-term trend is still down: it's above its 8-week average, but 50% below its 200-week average.
SOPH Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $7.57 | 3.8% above |
| 20 week MA | $7.25 | 8.4% above |
| 50 week MA | $5.87 | 34% above |
| 100 week MA | $4.68 | 68% above |
| 200 week MA | $4.35 | 81% above |
SOPH has the edge over NVO on trend strength, trading above more of its moving averages.
NVO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $29.1 | $34.7 | +19% |
| 2021 | $34.7 | $54.2 | +56% |
| 2022 | $54.2 | $67.0 | +24% |
| 2023 | $67.0 | $103.5 | +54% |
| 2024 | $103.5 | $87.4 | -16% |
| 2025 | $87.4 | $52.4 | -40% |
| 2026 YTD | $52.4 | $40.7 | -22% |
NVO has finished higher in four of the last six years, two of them by more than 50%. It's down 22% so far in 2026.
SOPH Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $16.8 | $13.7 | -19% |
| 2022 | $13.7 | $2.85 | -79% |
| 2023 | $2.85 | $4.71 | +65% |
| 2024 | $4.71 | $3.36 | -29% |
| 2025 | $3.36 | $4.73 | +41% |
| 2026 YTD | $4.73 | $7.86 | +66% |
SOPH has the edge over NVO on returns for 2026, with the stronger performance.